HeartBeam (BEAT) Competitors

$0.92 +0.00 (+0.31%)

Closing price 05/21/2026 04:00 PM Eastern

Extended Trading

$0.93 +0.01 (+0.81%)

As of 05/21/2026 07:59 PM Eastern

BEAT vs. ZEPP, AMWL, NYXH, HCAT, and MDXH

Should you buy HeartBeam stock or one of its competitors? MarketBeat compares HeartBeam with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HeartBeam include Zepp Health (ZEPP), American Well (AMWL), Nyxoah (NYXH), Health Catalyst (HCAT), and MDxHealth (MDXH). These companies are all part of the "medical info sys" industry.

How does HeartBeam compare to Zepp Health?

HeartBeam (NASDAQ:BEAT) and Zepp Health (NYSE:ZEPP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

HeartBeam has a beta of -0.86, suggesting that its share price is 186% less volatile than the broader market. Comparatively, Zepp Health has a beta of 2, suggesting that its share price is 100% more volatile than the broader market.

In the previous week, HeartBeam had 2 more articles in the media than Zepp Health. MarketBeat recorded 2 mentions for HeartBeam and 0 mentions for Zepp Health. Zepp Health's average media sentiment score of 0.00 beat HeartBeam's score of -0.17 indicating that Zepp Health is being referred to more favorably in the news media.

Company	Overall Sentiment
HeartBeam	Neutral
Zepp Health	Neutral

HeartBeam has higher earnings, but lower revenue than Zepp Health. Zepp Health is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
Zepp Health	$258.90M	0.51	-$40.07M	-$2.51	N/A

HeartBeam presently has a consensus target price of $4.83, indicating a potential upside of 425.08%. Zepp Health has a consensus target price of $56.28, indicating a potential upside of 526.38%. Given Zepp Health's higher possible upside, analysts clearly believe Zepp Health is more favorable than HeartBeam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Zepp Health	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartBeam has a net margin of 0.00% compared to Zepp Health's net margin of -15.48%. Zepp Health's return on equity of -15.00% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
Zepp Health	-15.48%	-15.00%	-6.07%

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 52.6% of Zepp Health shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by insiders. Comparatively, 36.0% of Zepp Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

HeartBeam and Zepp Health tied by winning 8 of the 16 factors compared between the two stocks.

How does HeartBeam compare to American Well?

HeartBeam (NASDAQ:BEAT) and American Well (NYSE:AMWL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

HeartBeam presently has a consensus price target of $4.83, indicating a potential upside of 425.08%. American Well has a consensus price target of $7.30, indicating a potential downside of 7.63%. Given HeartBeam's stronger consensus rating and higher possible upside, equities analysts clearly believe HeartBeam is more favorable than American Well.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
American Well	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

7.8% of HeartBeam shares are held by institutional investors. Comparatively, 56.1% of American Well shares are held by institutional investors. 18.0% of HeartBeam shares are held by company insiders. Comparatively, 11.8% of American Well shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

HeartBeam has a net margin of 0.00% compared to American Well's net margin of -37.02%. American Well's return on equity of -32.11% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
American Well	-37.02%	-32.11%	-24.12%

HeartBeam has a beta of -0.86, suggesting that its stock price is 186% less volatile than the broader market. Comparatively, American Well has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, HeartBeam had 1 more articles in the media than American Well. MarketBeat recorded 2 mentions for HeartBeam and 1 mentions for American Well. American Well's average media sentiment score of 0.49 beat HeartBeam's score of -0.17 indicating that American Well is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
American Well	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartBeam has higher earnings, but lower revenue than American Well. HeartBeam is trading at a lower price-to-earnings ratio than American Well, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
American Well	$249.32M	0.52	-$95.70M	-$5.42	N/A

Summary

HeartBeam beats American Well on 9 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and HeartBeam (NASDAQ:BEAT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

HeartBeam has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. Nyxoah's return on equity of -163.73% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
HeartBeam	N/A	-1,034.04%	-434.40%

7.8% of HeartBeam shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 18.0% of HeartBeam shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nyxoah had 1 more articles in the media than HeartBeam. MarketBeat recorded 3 mentions for Nyxoah and 2 mentions for HeartBeam. Nyxoah's average media sentiment score of 0.00 beat HeartBeam's score of -0.17 indicating that Nyxoah is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nyxoah presently has a consensus price target of $7.67, indicating a potential upside of 167.13%. HeartBeam has a consensus price target of $4.83, indicating a potential upside of 425.08%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

HeartBeam has lower revenue, but higher earnings than Nyxoah. HeartBeam is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$15.33M	7.26	-$101.92M	-$2.48	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A

Nyxoah has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, HeartBeam has a beta of -0.86, suggesting that its stock price is 186% less volatile than the broader market.

Summary

HeartBeam beats Nyxoah on 9 of the 16 factors compared between the two stocks.

How does HeartBeam compare to Health Catalyst?

HeartBeam (NASDAQ:BEAT) and Health Catalyst (NASDAQ:HCAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 85.0% of Health Catalyst shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 2.6% of Health Catalyst shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HeartBeam currently has a consensus target price of $4.83, indicating a potential upside of 425.08%. Health Catalyst has a consensus target price of $2.77, indicating a potential upside of 114.94%. Given HeartBeam's stronger consensus rating and higher probable upside, research analysts plainly believe HeartBeam is more favorable than Health Catalyst.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Health Catalyst	1 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.23

HeartBeam has a net margin of 0.00% compared to Health Catalyst's net margin of -87.69%. Health Catalyst's return on equity of -3.52% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
Health Catalyst	-87.69%	-3.52%	-1.77%

In the previous week, Health Catalyst had 3 more articles in the media than HeartBeam. MarketBeat recorded 5 mentions for Health Catalyst and 2 mentions for HeartBeam. HeartBeam's average media sentiment score of -0.17 beat Health Catalyst's score of -0.19 indicating that HeartBeam is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Health Catalyst	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartBeam has a beta of -0.86, suggesting that its share price is 186% less volatile than the broader market. Comparatively, Health Catalyst has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

HeartBeam has higher earnings, but lower revenue than Health Catalyst. HeartBeam is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
Health Catalyst	$311.14M	0.31	-$177.97M	-$3.72	N/A

Summary

HeartBeam beats Health Catalyst on 8 of the 15 factors compared between the two stocks.

How does HeartBeam compare to MDxHealth?

HeartBeam (NASDAQ:BEAT) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

HeartBeam presently has a consensus price target of $4.83, indicating a potential upside of 425.08%. MDxHealth has a consensus price target of $4.63, indicating a potential upside of 459.93%. Given MDxHealth's higher possible upside, analysts plainly believe MDxHealth is more favorable than HeartBeam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

HeartBeam has higher earnings, but lower revenue than MDxHealth. HeartBeam is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartBeam	N/A	N/A	-$21.01M	-$0.56	N/A
MDxHealth	$110.97M	0.37	-$33.52M	-$0.65	N/A

HeartBeam has a beta of -0.86, suggesting that its share price is 186% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

7.8% of HeartBeam shares are owned by institutional investors. 18.0% of HeartBeam shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

HeartBeam has a net margin of 0.00% compared to MDxHealth's net margin of -29.90%. HeartBeam's return on equity of -1,034.04% beat MDxHealth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-1,034.04%	-434.40%
MDxHealth	-29.90%	-1,078.01%	-22.51%

In the previous week, MDxHealth had 1 more articles in the media than HeartBeam. MarketBeat recorded 3 mentions for MDxHealth and 2 mentions for HeartBeam. HeartBeam's average media sentiment score of -0.17 beat MDxHealth's score of -0.36 indicating that HeartBeam is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MDxHealth	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

HeartBeam beats MDxHealth on 9 of the 15 factors compared between the two stocks.

Get HeartBeam News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BEAT vs. The Competition

Export

Metric	HeartBeam	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.71M	$1.46B	$6.35B	$12.29B
Dividend Yield	N/A	N/A	2.79%	5.33%
P/E Ratio	-1.64	64.06	21.08	25.34
Price / Sales	N/A	6.28	528.17	80.04
Price / Cash	N/A	22.77	44.13	56.16
Price / Book	46.03	6.36	10.00	7.01
Net Income	-$21.01M	-$54.76M	$3.55B	$335.27M
7 Day Performance	-4.61%	5.64%	1.99%	1.28%
1 Month Performance	-1.47%	10.59%	-0.87%	0.16%
1 Year Performance	-41.92%	1.41%	36.38%	34.54%

HeartBeam Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BEAT HeartBeam	4.0148 of 5 stars	$0.92 +0.3%	$4.83 +425.1%	-41.9%	$37.71M	N/A	N/A	1,700	Gap Down
ZEPP Zepp Health	2.2499 of 5 stars	$10.87 +13.8%	$56.28 +417.9%	+248.9%	$156.99M	$258.90M	N/A	1,230	Upcoming Earnings
AMWL American Well	1.9007 of 5 stars	$7.70 -2.5%	$7.30 -5.1%	+6.2%	$127.44M	$249.32M	N/A	1,040
NYXH Nyxoah	1.871 of 5 stars	$3.00 -2.3%	$7.67 +155.6%	-64.3%	$116.28M	$10.02M	N/A	110	Gap Up
HCAT Health Catalyst	2.2418 of 5 stars	$1.35 -8.9%	$2.77 +105.7%	-65.5%	$98.98M	$311.14M	N/A	1,200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BEAT) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HeartBeam (BEAT) Competitors

BEAT vs. ZEPP, AMWL, NYXH, HCAT, and MDXH

How does HeartBeam compare to Zepp Health?

Summary

How does HeartBeam compare to American Well?

Summary

How does HeartBeam compare to Nyxoah?

Summary

How does HeartBeam compare to Health Catalyst?

Summary

How does HeartBeam compare to MDxHealth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HeartBeam (BEAT) Competitors

BEAT vs. ZEPP, AMWL, NYXH, HCAT, and MDXH

How does HeartBeam compare to Zepp Health?

Which has more volatility & risk, BEAT or ZEPP?

Does the media favor BEAT or ZEPP?

Which has better earnings and valuation, BEAT or ZEPP?

Do analysts rate BEAT or ZEPP?

Is BEAT or ZEPP more profitable?

Do institutionals and insiders believe in BEAT or ZEPP?

Summary

How does HeartBeam compare to American Well?

Do analysts rate BEAT or AMWL?

Do institutionals & insiders have more ownership in BEAT or AMWL?

Is BEAT or AMWL more profitable?

Which has more volatility and risk, BEAT or AMWL?

Does the media favor BEAT or AMWL?

Which has stronger valuation and earnings, BEAT or AMWL?

Summary

How does HeartBeam compare to Nyxoah?

Is NYXH or BEAT more profitable?

Do institutionals & insiders believe in NYXH or BEAT?

Does the media prefer NYXH or BEAT?

Do analysts prefer NYXH or BEAT?

Which has preferable valuation & earnings, NYXH or BEAT?

Which has more volatility & risk, NYXH or BEAT?

Summary

How does HeartBeam compare to Health Catalyst?

Do institutionals and insiders believe in BEAT or HCAT?

Do analysts prefer BEAT or HCAT?

Is BEAT or HCAT more profitable?

Does the media prefer BEAT or HCAT?

Which has more risk and volatility, BEAT or HCAT?

Which has stronger earnings and valuation, BEAT or HCAT?

Summary

How does HeartBeam compare to MDxHealth?

Do analysts prefer BEAT or MDXH?

Which has better earnings & valuation, BEAT or MDXH?

Which has more risk & volatility, BEAT or MDXH?

Do institutionals & insiders believe in BEAT or MDXH?

Is BEAT or MDXH more profitable?

Does the media prefer BEAT or MDXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAT vs. The Competition

HeartBeam Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools